Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Anthony B. El-Khoueiry1*, Tim Meyer2, Ann-Lii Cheng3, Lorenza Rimassa4,5, Suvajit Sen6, Steven Milwee6, Robin Kate Kelley7 and Ghassan K. Abou-Alfa8,9

Abstract

Background: Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC and Child–Pugh A liver cirrhosis at baseline, was evaluated for outcomes in patients who had Child–Pugh B cirrhosis at Week 8.

Methods: This was a retrospective analysis of adult patients with previously treated advanced HCC. Child–Pugh B status was assessed by the investigator. Patients were randomised 2:1 to cabozantinib (60 mg once daily) or placebo.

Results: Fifty-one patients receiving cabozantinib and 22 receiving placebo had Child–Pugh B cirrhosis at Week 8. Safety and tolerability of cabozantinib for the Child–Pugh B subgroup were consistent with the overall population. For cabozantinib– versus placebo-treated patients, median OS from randomisation was 8.5 versus 3.8 months (HR 0.32, 95% CI 0.18–0.58), median PFS was 3.7 versus 1.9 months (HR 0.44, 95% CI 0.25–0.76), and best response was stable disease in 57% versus 23% of patients.

Conclusions: These encouraging results with cabozantinib support the initiation of prospective studies in patients with advanced HCC and Child–Pugh B liver function.

Clinical Trial Registration: NCT01908426.

Keywords: Cabozantinib, Child–Pugh B, Hepatocellular carcinoma
these trials excluded patients with poor liver function (Child–Pugh B or worse hepatic dysfunction). Further, underlying liver cirrhosis represents a competing risk of death in patients with HCC and Child–Pugh B cirrhosis; therefore, the benefit of anticancer therapy is difficult to evaluate in non-randomised studies. Consequently, limited data are available for the use of systemic therapies in patients with advanced liver cirrhosis, resulting in a lack of treatment options for this population [6–8].

Cabozantinib is a tyrosine kinase inhibitor with targets that include MET, VEGFR, and the TAM family of receptor kinases and is approved for patients with HCC who have been previously treated with sorafenib [9, 10]. In the pivotal phase 3 CELESTIAL trial (NCT01908426), cabozantinib, as second- or third-line therapy, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced HCC and Child–Pugh A liver cirrhosis [11]. Median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (hazard ratio [HR] 0.76; 95% confidence interval [CI] 0.63–0.92; \( p = 0.005 \)), and median PFS was 5.2 months with cabozantinib versus 1.9 months with placebo (HR 0.44; 95% CI 0.36–0.52; \( p < 0.001 \)) [11].

We present a post hoc retrospective evaluation of the safety and efficacy of cabozantinib in patients from CELESTIAL with Child–Pugh A liver cirrhosis who progressed to Child–Pugh B cirrhosis at Week 8. The objective of this analysis was to characterise clinical outcomes in this cohort of patients.

Methods
This is a retrospective analysis of outcomes from CELESTIAL for the subgroup of patients who had Child–Pugh B cirrhosis, as assessed by the investigator, by Week 8 (time of first Child–Pugh assessment and the first radiographic assessment after randomisation). Child–Pugh scoring was also independently determined retrospectively by the Biostatistics and Clinical Data Management (BCDM) department at Exelixis Inc. (study sponsor), based on investigator assessments for ascites and hepatic encephalopathy and central laboratory assessments. CELESTIAL study details have been previously published for the efficacy and safety results for the overall population [11]. The study allowed adult patients with advanced HCC, Child–Pugh class A liver function, and Eastern Cooperative Oncology Group performance status of 0 or 1 [11]. Patients must have received prior sorafenib and could have received up to two prior systemic regimens [11]. Patients were randomised 2:1 to receive cabozantinib 60 mg once daily or matched placebo [11]. Randomisation was performed with an interactive response system and permuted blocks. Randomisation was stratified by disease aetiology (hepatitis B virus [HBV], with or without hepatitis C virus [HCV]; HCV without HBV; or non-viral), geographic region (Asia or other), and extrahepatic spread of disease, macrovascular invasion, or both (yes or no). The outcomes reported in this retrospective analysis are safety, with assessments starting from study initiation; OS; and investigator-assessed PFS and tumour response per RECIST v1.1. Overall survival was defined as the time from randomisation to death from any cause; progression-free survival was defined as the time from randomisation to radiographic progression or death from any cause, whichever occurred first; objective response rate was defined as the percentage of patients with a confirmed complete or partial response. Adverse events (AEs) were reported according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 [12]. Radiographic assessment by computed tomography or magnetic resonance imaging was conducted every 8 weeks after randomisation with a follow-up assessment conducted 8 weeks after radiographic progression or treatment discontinuation. Safety was assessed continuously with a final assessment 30 days after treatment discontinuation. Patients who were Child–Pugh A at Week 8 or patients who did not have a Child–Pugh assessment at Week 8 were excluded from this retrospective analysis; patients with Child–Pugh C status at Week 8 were also excluded as cabozantinib should be avoided in patients with severe hepatic impairment. The data cutoff date was 1 June 2017.

Results

Patient Population
At randomisation, nearly all patients had investigator-assessed Child–Pugh class A cirrhosis, with seven patients in the cabozantinib arm and two patients in the placebo arm assessed to have Child–Pugh B cirrhosis and noted as protocol deviations. Three out of a total of nine patients with Child–Pugh B status at baseline had Week 8 data, with all being in the cabozantinib group; one remained with Child–Pugh B and two were assessed with Child–Pugh A at Week 8. At the time of the first Child–Pugh assessment at Week 8 after randomisation, 51/470 patients in the cabozantinib arm and 22/237 patients in the placebo arm had investigator-assessed Child–Pugh B cirrhosis (Child–Pugh B subgroup). Child–Pugh status at Week 8 was unknown for 288 patients in the overall study population (194 for cabozantinib and 94 for placebo), Child–Pugh A for 343 patients (223 and 120), and Child–Pugh C for 3 patients (2 and 1); these patients were excluded from this retrospective analysis. Cabozantinib and placebo were received for ≥8 weeks by 94% (48/51) and 82% (18/22) of patients, respectively, for the Child–Pugh B cohort and 80% (375/467) and
76% (135/237) of patients, respectively, for the overall population. As of data cutoff, the percent (n) of patients who were still on cabozantinib/placebo was 6% (3)/0 for the Child–Pugh B cohort and 16% (73)/11% (26) for the overall population.

For patients with investigator-assessed Child–Pugh B status at Week 8, the majority (64%) had a BCDM-determined Child–Pugh score of A6 at baseline and 27% had a Child–Pugh score of A5, whereas 7% had a score ≥7 and 1% of scores were missing (Table 1). Among those who still had investigator-assessed Child–Pugh A cirrhosis at Week 8, 26% (90/341) had BCDM-determined Child–Pugh A6 status and 72% (246/341) had A5 status at baseline. In the overall CELESTIAL patient population, 37% had Child–Pugh A6 status and 59% had Child–Pugh A5 status at baseline. At least half of the patients (51%) in the Child–Pugh B subgroup had a Child–Pugh score of 7 at Week 8, whereas 19% and 11% had Child–Pugh scores of 8 and 9, respectively (Table 2). Point changes from baseline in the levels of albumin, bilirubin, and ascorbic acid were the most common contributors to the development of the Child–Pugh B status at Week 8 for patients in both the cabozantinib and placebo arms. At Week 8, greater changes from baseline were observed for the Child–Pugh B subgroup versus the overall population in various liver function parameters, including liver enzyme activity (i.e., alkaline phosphatase), and albumin and bilirubin levels (Additional file 1, Table 1).

Patients in the Child–Pugh B subgroup tended to have higher baseline rates of albumin-bilirubin (ALBI) grades 2/3 compared with the overall study population (92% vs. 59%), macrovascular invasion (40% vs. 30%), and prior transarterial chemoembolisation for HCC (53% vs. 44%), whereas aetiology of hepatitis B virus (HBV) tended to be lower (33% vs. 38%) (Table 1). In the Child–Pugh B subgroup, patients in the cabozantinib arm versus the placebo arm tended to have higher baseline rates of macrovascular invasion (43% vs. 32%), extrahepatic spread (82% vs. 68%), alpha-fetoprotein ≥400 ng/mL (39% vs. 27%), HBV (35% vs. 27%), and hepatitis C virus (31% vs. 18%). Additionally, for the Child–Pugh B subgroup, the cabozantinib arm in comparison with the placebo arm tended to have a higher baseline rate of ALBI grade 1 (10% vs. 5%) and a lower rate of ALBI grade 2 (88% vs. 95%).

Safety and Tolerability
For patients assigned to cabozantinib, the median average daily dose (36.9 mg), the median duration of exposure (3.7 months), and the rates of dose reduction (61%) and discontinuation (18%) due to treatment-related AEs for patients in the Child–Pugh B subgroup were similar to the overall cabozantinib group (Table 3). Grade 3/4 all-causality AEs in the cabozantinib arm were experienced by 71% of patients in the Child–Pugh B subgroup compared with 68% overall. The rates of the most common grade 3/4 AEs were numerically higher in the Child–Pugh B subgroup compared with the overall cabozantinib group for fatigue (20% vs. 10%), ascites (14% vs. 4%), and thrombocytopenia (12% vs. 3%) and lower for palmar-plantar erythrodysesthesia (8% vs. 17%) and hypertension (8% vs. 16%). Rates of grade 3/4 AEs associated with liver toxicity were generally similar for the Child–Pugh B subgroup compared with the overall cabozantinib group, with rates comparable for increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and higher for increased bilirubin (10% vs. 3%). The occurrence of grade 3/4 AEs associated with cirrhosis decompensation was greater for the Child–Pugh B subgroup than the overall cabozantinib group for ascites, indicated previously, and hepatic encephalopathy (6% vs. 3%).

For patients assigned to placebo, 59% in the Child–Pugh B subgroup and 36% overall experienced grade 3/4 all-causality AEs. Higher rates of Grade 3/4 AEs were reported in the Child–Pugh B subgroup relative to the overall placebo group for fatigue (18% vs. 4%) and ascites (23% vs. 5%), whereas rates were comparable for increased ALT, AST, and bilirubin.

Efficacy Outcomes
In the Child–Pugh B subgroup, median OS was 8.5 months for patients receiving cabozantinib versus 3.8 months for patients receiving placebo (HR 0.32, 95% CI 0.18–0.58) (Fig. 1A). Median PFS was 3.7 months with cabozantinib versus 1.9 months with placebo (HR 0.44, 95% CI 0.25–0.76) (Fig. 1B). There were no complete or partial responses in the Child–Pugh B subgroup. Stable disease as a best objective response was obtained by 57% of patients in the cabozantinib arm versus 23% of patients in the placebo arm of the Child–Pugh B subgroup (Table 4). These results are consistent with those reported for the overall study population.

For the overall study population, median OS was 10.2 months with cabozantinib and 8.0 months with placebo (HR 0.76; 95% CI 0.63–0.92), whereas median PFS was 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44; 95% CI 0.36–0.52) and stable disease was obtained by 60% and 33% of patients, respectively [11].

Discussion
This exploratory analysis evaluated the safety and efficacy of cabozantinib in patients from CELESTIAL whose liver function deteriorated to Child–Pugh B status by Week 8 at the time of the first Child–Pugh investigator assessment. A majority of these patients had a Child–Pugh score of 6 at baseline, as determined
| Table 1  Baseline characteristics of Child–Pugh B subgroup | **Child–Pugh B subgroup** | **Overall population**<sup>a</sup> |
|-----------------|--------------------|---------------------------|
|                  | Cabozantinib  (N = 51) | Placebo  (N = 22) | Total  (N = 73) | Cabozantinib  (N = 470) | Placebo  (N = 237) | Total  (N = 707) |
| Median age (range), years | 63.0 (22–82) | 64.5 (50–85) | 64.0 (22–85) | 64 (22–86) | 64 (24–86) | 64 (22–86) |
| Male, n (%) | 45 (88) | 20 (91) | 65 (89) | 379 (81) | 202 (85) | 581 (82) |
| Geographic region, n (%) | | | | | | |
| Asia | 14 (27) | 3 (14) | 17 (23) | 116 (25) | 59 (25) | 175 (25) |
| Europe | 21 (41) | 12 (55) | 33 (45) | 231 (49) | 108 (46) | 339 (48) |
| Australian/New Zealand | 1 (2) | 1 (5) | 2 (3) | 15 (3) | 11 (5) | 26 (4) |
| Canada/USA | 15 (29) | 6 (27) | 21 (29) | 108 (23) | 59 (25) | 167 (24) |
| Race, n (%) | | | | | | |
| Asian | 17 (33) | 5 (23) | 22 (30) | 159 (34) | 82 (35) | 241 (34) |
| White | 30 (59) | 14 (64) | 44 (60) | 264 (56) | 130 (55) | 394 (56) |
| Black | 0 | 2 (9) | 2 (3) | 8 (2) | 11 (5) | 19 (3) |
| Other | 1 (2) | 1 (5) | 2 (3) | 8 (2) | 2 (1) | 10 (1) |
| Not reported | 3 (6) | 0 | 3 (4) | 31 (7) | 12 (5) | 43 (6) |
| ECOG status, n (%) | | | | | | |
| 0 | 27 (53) | 12 (55) | 39 (53) | 245 (52) | 131 (55) | 376 (53) |
| 1 | 24 (47) | 10 (45) | 34 (47) | 224 (48) | 106 (45) | 330 (47) |
| 2 | 0 | 0 | 0 | 1 (< 1) | 0 | 1 (< 1) |
| Aetiology of disease, n (%) | | | | | | |
| HBV | 18 (35) | 6 (27) | 24 (33) | 178 (38) | 89 (38) | 267 (38) |
| HCV | 16 (31) | 4 (18) | 20 (27) | 113 (24) | 55 (23) | 168 (24) |
| Alcohol use | 19 (37) | 4 (18) | 23 (32) | 112 (24) | 39 (16) | 151 (21) |
| Nonalcoholic steatohepatitis | 3 (6) | 2 (9) | 5 (7) | 43 (9) | 23 (10) | 66 (9) |
| AFP, n (%) | | | | | | |
| < 400 ng/mL | 31 (61) | 16 (73) | 47 (64) | 278 (59) | 136 (57) | 414 (59) |
| ≥ 400 ng/mL | 20 (39) | 6 (27) | 26 (36) | 192 (41) | 101 (43) | 293 (41) |
| Albumin, n (%) | | | | | | |
| < 35 g/L | 27 (53) | 11 (50) | 38 (52) | 131 (28) | 60 (25) | 191 (27) |
| ≥ 35 g/L | 24 (47) | 11 (50) | 35 (48) | 339 (72) | 177 (75) | 516 (73) |
| Bilirubin, n (%) | | | | | | |
| < 22.23 µmol/L | 40 (78) | 20 (91) | 60 (82) | 421 (90) | 221 (93) | 642 (91) |
| ≥ 22.23–< 29.07 µmol/L | 6 (12) | 2 (9) | 8 (11) | 37 (8) | 13 (5) | 50 (7) |
| ≥ 29.07 µmol/L | 5 (10) | 0 | 5 (7) | 12 (3) | 3 (1) | 15 (2) |
| Extrahepatic spread of disease and/or macrovascular invasion, n (%) | | | | | | |
| Extrahepatic spread of disease | 47 (92) | 17 (77) | 64 (88) | 398 (85) | 200 (84) | 598 (85) |
| Macrovascular invasion | 42 (82) | 15 (68) | 57 (78) | 369 (79) | 182 (77) | 551 (78) |
| ALBI grade, n (%) | | | | | | |
| 1 | 5 (10) | 1 (5) | 6 (8) | 186 (40) | 102 (43) | 288 (41) |
| 2 | 45 (88) | 21 (95) | 66 (90) | 282 (60) | 133 (56) | 415 (59) |
| 3 | 1 (2) | 0 | 1 (1) | 2 (< 1) | 2 (1) | 4 (1) |
| Child–Pugh score, n (%)<sup>b</sup> | | | | | | |
| 5 | 13 (25) | 7 (32) | 20 (27) | 264 (56) | 153 (65) | 417 (59) |
| 6 | 33 (65) | 14 (64) | 47 (64) | 183 (39) | 78 (33) | 261 (37) |
| ≥ 7 | 4 (8) | 1 (5) | 5 (7) | 17 (4) | 5 (2) | 22 (3) |
| Missing | 1 (2) | 0 | 1 (1) | 6 (1) | 1 (< 1) | 7 (1) |
| Sites of disease, n (%) | | | | | | |
| Liver | 45 (88) | 21 (95) | 66 (90) | 395 (84) | 216 (91) | 611 (86) |
| Bone | 9 (18) | 2 (9) | 11 (15) | 60 (13) | 34 (14) | 94 (13) |
by BCDM, whereas most of the patients who still had Child–Pugh A status at Week 8 had a Child–Pugh score of 5. Although investigator-assessed Child–Pugh grading and BCDM-determined Child–Pugh scoring were done independently, the majority of determinations were concordant. Cabozantinib appeared to have a manageable safety profile in the Child–Pugh B subgroup, with comparable rates to the overall cabozantinib group for dose reductions and discontinuations due to treatment-related AEs [11]. However, there were differences in the rates of some grade 3/4 AEs, including higher rates of fatigue, ascites, and thrombocytopenia in the Child–Pugh B subgroup compared with the overall cabozantinib group [11]. Higher rates of some grade 3/4 AEs were also noted in the placebo arm for the Child–Pugh B subgroup relative to the overall placebo group. As these grade 3/4 AEs occurred throughout the study, their incidence could be associated with reduced liver function, the course of the disease, or both. The higher incidence of thrombocytopenia with cabozantinib versus placebo in both the retrospective cohort and the overall study population and the absence of events in the placebo arm of the retrospective cohort could indicate an association with cabozantinib treatment. These data are consistent with the expected clinical manifestations of more advanced cirrhosis and portal hypertension [13–15], and suggest that patients with Child–Pugh B cirrhosis are at greater risk of experiencing treatment-emergent or treatment-related AEs compared with patients with Child–Pugh A cirrhosis, which represents nearly all of patients in the overall population.

Hazard ratios for OS and PFS indicate clinical benefit with cabozantinib in the Child–Pugh B subgroup. The outcomes with cabozantinib in patients with HCC and compromised liver function presented here are also supported by the outcomes of a CELESTIAL subgroup analysis based on baseline ALBI grades (an objective measure of liver function with higher grades associated with worse prognosis [16]) [17]. In the analysis by ALBI grade, a trend of improved OS and PFS with cabozantinib compared with placebo was observed irrespective of baseline grade [17]. It should be noted that a majority of patients in the Child–Pugh B subgroup had ALBI grade 2 cirrhosis at baseline.

### Table 1 (continued)

|                         | Child–Pugh B subgroup | Overall populationa |
|-------------------------|-----------------------|---------------------|
|                         | Cabozantinib (N = 51) | Placebo (N = 22)    | Total (N = 73) |
|                         | (N = 470)             | (N = 237)           | (N = 707)      |
| Visceral (excluding liver) | 24 (47)               | 9 (41)              | 33 (45)        | 215 (46)       | 105 (44)       | 320 (45)       |
| Lymph node              | 19 (37)               | 3 (14)              | 22 (30)        | 155 (33)       | 71 (30)        | 226 (32)       |

| Number of prior systemic anticancer regimens for advanced HCC, n (%) | 0 | 1 | 2 | ≥3 | 0 | 3 (< 1) |
|---------------------------------------------------------------------|---|---|---|----|---|--------|
| Visceral (excluding liver)                                          | 1 (2) | 33 (65) | 16 (31) | 1 (2) | 1 (2) | 3 (1) |
| Lymph node                                                          | 0 | 13 (59) | 9 (41) | 0 | 1 (1) | 0 |
| Total                                                               | 1 (1) | 46 (63) | 25 (34) | 2 (1) | 1 (1) | 3 (1) |
| TACE for HCC, N (%)                                                 | 26 (51) | 13 (59) | 39 (53) | 203 (43) | 111 (47) | 314 (44) |
| Median total duration of prior sorafenib (range), months            | 5.4 (1.1–40.0) | 7.1 (1.0–29.2) | 5.4 (1.0–40.0) | 5.3 (0.3–70.0) | 4.8 (0.2–76.8) | 5.2 (0.2–76.8) |
| Median time from disease progression to randomisation (range), mo²  | 1.5 (0.2–100.8) | 1.9 (0.4–69.4) | 1.5 (0.2–100.8) | 1.6 (0.0–100.8) | 1.7 (0.2–69.4) | 1.6 (0.0–100.8) |

*Data from Abou-Alfa et al. N. Engl. J. Med. 379, 54–63 (2018) [11]. *As Child–Pugh grading was investigator assessed and Child–Pugh scoring was determined retrospectively by BCDM, some discrepancies between grading and scoring results existed. *n* = 49 and 21 for cabozantinib and placebo cohorts, respectively. AFP alpha fetoprotein, ALBI albumin-bilirubin, BCDM Biostatistics and Clinical Data Management, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCV hepatitis C virus, TACE transarterial chemoembolisation.

### Table 2

Child–Pugh scores at Week 8

| Patients with Child–Pugh B at Week 8, n | Patients with available BCDM-determined Child–Pugh score points, n a | Child–Pugh score (Week 8) n (%) b | 7 points | 8 points | 9 points |
|----------------------------------------|---------------------------------------------------------------|---------------------------------|---------|---------|---------|
| Cabozantinib 51                        | 42                                                           | 26 (51) | 11 (22) | 3 (6)   |
| Placebo 22                             | 21                                                           | 11 (50) | 3 (14)  | 5 (23)  |

a Two patients each in the cabozantinib and placebo cohorts had a score of 6. As Child–Pugh grading was investigator assessed and Child–Pugh scoring was determined independently by BCDM, some discrepancies between grading and scoring results existed. bPercentage of total number of patients who developed Child–Pugh B cirrhosis. BCDM Biostatistics and Clinical Data Management.
The observed outcomes of cabozantinib in patients with reduced liver function should be interpreted with caution because of the retrospective nature of subgroup analyses and the relatively small size of the Child–Pugh B subgroup. As CELESTIAL did not allow for patients with Child–Pugh B status at study entry, we chose to analyse data from patients who developed Child–Pugh B cirrhosis on treatment. Further, 288/707 patients (41%)

| Table 3 Safety and tolerability of cabozantinib (safety population) |
|---------------------------------------------------------------|
| **Child–Pugh B subgroup**                                      |
| **Caborzantinib (N = 51)** vs **Placebo (N = 22)** |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- |
| Median duration of exposure (range), months | 3.7 (1.4–12.9) | 2.0 (0.9–5.5) | 3.8 (0.1–37.3) | 2.0 (0.0–27.2) |
| Median average daily dose (range), mg | 36.9 (12.5–60.0) | 56.8 (17.9–60.0) | 35.8 (11.6–60.0) | 58.9 (12.0–60.0) |
| Dose reduction, n (%) | 31 (61) | 3 (14) | 291 (62) | 30 (13) |
| Discontinuation due to treatment-related AE, n (%) | 9 (18) | 1 (5) | 74 (16) | 6 (2.5) |
| **Overall population**                                        |
| **Caborzantinib (N = 467)** vs **Placebo (N = 237)** |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- |
| Median duration of exposure (range), months | 3.7 (1.4–12.9) | 2.0 (0.9–5.5) | 3.8 (0.1–37.3) | 2.0 (0.0–27.2) |
| Median average daily dose (range), mg | 36.9 (12.5–60.0) | 56.8 (17.9–60.0) | 35.8 (11.6–60.0) | 58.9 (12.0–60.0) |
| Dose reduction, n (%) | 31 (61) | 3 (14) | 291 (62) | 30 (13) |
| Discontinuation due to treatment-related AE, n (%) | 9 (18) | 1 (5) | 74 (16) | 6 (2.5) |

*Data from Abou-Alfa et al. N. Engl. J. Med. 379, 54–63 (2018) [11]. AE of any cause that occurred at an rate of > 5% for Grade 3/4 in either treatment arm of the Child–Pugh B subgroup or in the overall study population. Sorted by Grade 3/4 in the cabozantinib arm. Assessments starting from study initiation. AE adverse event, ALT alanine aminotransferase, ALP alkaline phosphatase, AST aspartate aminotransferase, PPE palmar-plantar erythrodysesthesia syndrome.
Fig. 1  Overall survival and progression-free survival in the Child–Pugh B subgroup. CI, confidence interval; mo, months; no, number; OS, overall survival; PFS, progression-free survival.
had unknown Child–Pugh status at Week 8. Prospective studies are required to further assess the efficacy and safety of cabozantinib in this patient population with Child–Pugh B status at start of therapy. A dose-escalation study in patients with HCC and Child–Pugh B cirrhosis will evaluate cabozantinib at three doses—20 mg, 40 mg, and 60 mg (NCT04497038) [18].

Previous retrospective and prospective studies have evaluated sorafenib, nivolumab, and regorafenib in patients with HCC and Child–Pugh B liver cirrhosis [19–24]. These studies focused on comparing Child Pugh A versus B; whereas this current study focused on outcomes in Child–Pugh B patients, as it was a retrospective subgroup analysis of a randomised study. In a prospective feasibility study of 300 patients with HCC treated with sorafenib, patients with Child–Pugh B cirrhosis had shorter PFS, time to progression, and OS than patients with Child–Pugh A status, with similar safety profiles [22]. In the GIDEON observational registry study of 3202 patients with HCC receiving sorafenib, including 666 patients with Child–Pugh B status, the incidence and type of AEs were consistent across Child–Pugh subgroups, with median overall survival longer for patients with Child–Pugh A status than for patients with Child–Pugh B status, with similar safety profiles [22]. In the CheckMate 040 study, treatment-related AEs associated with nivolumab from the CheckMate 040 study, treatment-related AEs associated with nivolumab resulting in treatment discontinuation were comparable with those for patients with Child–Pugh A cirrhosis, with a median OS in patients with Child–Pugh B status of 7.6 months [24]. In the REFINE observational study of patients with HCC, median OS with regorafenib was 16.0 months in patients with Child–Pugh A status compared with 8.0 months in patients with Child–Pugh B status [23]. In addition to these agents, cytotoxic anticancer agents have been evaluated in this patient population and have shown some level of efficacy and safety [25, 26].

Patients with Child–Pugh B cirrhosis and HCC have poor prognosis and considerable unmet medical need.

The results presented in this retrospective analysis suggest encouraging safety and efficacy outcomes with cabozantinib in this patient population. Prospective studies involving cabozantinib are warranted in patients with advanced HCC and Child–Pugh B liver function.

**Abbreviations**

AE: Adverse event; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BDCM: Biostatistics and Clinical Data Management; CI: Confidence interval; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09453-z.

**Additional file 1.**

**Acknowledgements**

Medical writing assistance provided by Alan Saltzman, PhD, and Bryan Thibodeau, PhD (Fishawack Communications, Conshohocken, PA) and funded by Exelixis. Tim Meyer is part funded by the NIHR UCH Biomedical Research Centre.

**Authors’ contributions**

ABEK, TM, ALC, LR, SM, RKK, and GKAA contributed to the conception of the manuscript and interpretation of data. SS contributed to the conception and drafting of the manuscript and interpretation of data. All authors provided critical review and revisions, and all authors approved the final version of the manuscript for submission and publication.

**Funding**

This study was supported by Exelixis, Inc.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

CELESTIAL was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the ethics committee/institutional review board of participating study centres (supplementary file). All patients provided written informed consent. This study adhered to CONSORT guidelines [11].

**Table 4** Tumour response

| Best overall response, n (%) | Child–Pugh B subgroup | Overall population* |
|-----------------------------|-----------------------|---------------------|
|                             | Cabozantinib (N = 51) | Placebo (N = 22)    |
| Complete response            | 0                     | 0                   |
| Partial response             | 0                     | 18 (4)              |
| Stable disease               | 29 (57)               | 5 (23)              |
| Progressive disease          | 21 (41)               | 15 (68)             |
| Not evaluable or missing     | 1 (2)                 | 2 (9)               |

| Overall population*          | Cabozantinib (N = 467) | Placebo (N = 237) |
|------------------------------|-------------------------|--------------------|
| Complete response            | 0                       | 0                  |
| Partial response             | 18 (4)                  | 1 (<1)             |
| Stable disease               | 282 (60)                | 78 (33)            |
| Progressive disease          | 98 (21)                 | 131 (55)           |
| Not evaluable or missing     | 72 (15)                 | 27 (11)            |

* Data from Abou-Alfa et al. N. Engl. J. Med. 379, 54–63 (2018) [11]
Consent for publication
Not applicable.

Competing interests
ABEK: Consulting/advisory: AstraZeneca, Bayer, BMS, Celgene, CytoMx, Eisai, Exelixis, Novartis, Roche; grant support: AstraZeneca, Astex; speakers' bureau fee: Merck.
TM: Grant support/consulting: Bayer, BMS, BTG, Eisai, Merck.
AHC: Honorarium: Bayer, Eisai, Merck, Merck Serono, Novartis, Ono Pharma., Roche, IQVIA; consulting/advisory: Bayer, BMS, Eisai, Exelixis, IQVIA, Merck Serono, Novartis, Nucleix, Ono Pharma., Roche; speaker bureau fees: Amgen, Bayer, Novartis, Eisai, Ono Pharma. Yakuhan.
LR: Consulting/advisory: Amgen, ArQule, AstraZeneca, Baselisa, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IpsiA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Zymeworks; speakers bureau fee: AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi; travel fee: Ipsen; research funding: Agios; ARMO BioSciences, AstraZeneca, Beigene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD; Nerviano Medical Sciences, Roche, Zymeworks.
SS, SM: Employees of Exelixis.

RKK: Consulting/advisory: Agios, AstraZeneca, BMS, Exact Sciences, Genentech/Roche, Gilead, Ipsen, Merck; research funding: Adaptimmune, Agios; AstraZeneca, Bayer, BMS, Celgene, Eli Lilly, EMD Serono, Exelixis, MedImmune, Merck, Novartis, Partner Therapeutics, Taiho Pharmaceuticals.
GKAA: Grant support: ActaBiologica, Agios, AstraZeneca, Bakuvia, BMS, Celerion, Celgene, CytomX, Debiopharm, Eisai, Eli Lilly, Flatiron, Genentech/Roche, Gilead, Incyte, Ipsen, IpsiA, Lilly, Merck, Mina, Polaris, QED, Redhill, Silaire, Sobx, Sobi, Therabionics, Twoxar, Vector, Yiviva.

Author details
1. USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. 2. Royal Free Hospital, University College London, London, UK. 3. National Taiwan University Hospital, Taipei, Taiwan. 4. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. 5. Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 6. Exelixis, Inc, Alameda, CA, USA. 7. UCSF Helen Diller Family Comprehensive Cancer Center, CA, San Francisco, USA. 8. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Weill Medical College at Cornell University, New York, NY, USA.

Received: 22 September 2021 Accepted: 16 March 2022
Published online: 09 April 2022

References
1. Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: from diagnosis to treatment. World J Hepatol. 2015;7:1020–8. https://doi.org/10.4254/wjh.v7.i8.1020.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91. https://doi.org/10.1200/JCO.2008.20.7753.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. https://doi.org/10.1002/ijic.25516.
4. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2. https://doi.org/10.1002/hep.24199.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;66:327–286. https://doi.org/10.1016/j.jhep.2011.12.001.
6. Heinrich JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80. https://doi.org/10.1002/hep.29086.
7. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50. https://doi.org/10.1002/hep.29913.
8. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Hepatobiliary cancers Version 2.2021. 2021 Date Accessed: 25 May 2021. Available from: https://www.nccn.org/professionals/physician_dg/PDF/hepatobiliary.pdf.
9. Cabometyx prescribing information, Exelixis, Inc (Alameda, CA, USA). 2020 Date Accessed: 19 Oct 2020. Available from: https://www.cabometyx.com/downloads/CABOMETYX-PI.pdf.
10. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298–308. https://doi.org/10.1158/1535-7163.MCT-11-0264.
11. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimmassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63. https://doi.org/10.1056/NEJMoa1717002.
12. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; Published: May 28, 2009 (v4.03: June 14, 2010) by the National Cancer Institute, 2010 Date Accessed: 20 Oct 2020. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x11.pdf.
26. Palmieri C, Macpherson IR. A review of the evidence base for utilizing
Child-Pugh criteria for guiding dosing of anticancer drugs in patients
with cancer and liver impairment. ESMO Open. 2021;6:100162. https://
doi.org/10.1016/j.esmoop.2021.100162.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.